Q-omics provides the consensus-scored GP5 profile across patient tissues and cancer cell-line models. GP5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, GP5 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, GP5 RNA expression shows 16,689 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight HNSC, THCA, and DLBC as cancer lineages where GP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GP5 survival associations across molecular data types. GP5 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GP5 RNA expression–survival associations across cancer types. High GP5 expression shows unfavorable associations in ACC, THCA, ESCA and LGG, but favorable associations in HNSC and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for GP5 RNA expression.
This table summarizes GP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for GP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GP5 shows lower tumor expression in THCA, KICH, UCEC, LUSC and KIRP and higher tumor expression in KIRC. The THCA box plot shows higher GP5 RNA expression in normal versus tumor tissue (log2 FC = −0.717, t-test p < 0.001).
This table shows molecular features associated with GP5 in patient tissues and cancer cell lines. In patient samples, GP5 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, GP5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
